Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Less is more: why rare disease funding is on the up

Despite reductions in R&D spending, clinical trials for rare diseases are going full steam ahead. Elly Earls speaks to Alastair Kent of Genetic Alliance UK, Tim Cote of the National Organization for Rare Disorders (NORD) and Dr Steve Groft of the Office of Rare Diseases Research (ORDR) on why drug development should not be affected by the sector's ever-decreasing budget.

Go Top